Clinical and laboratory characteristics of 36 patients with BL
| . | Whole series . | BIM methylated . | BIM unmethylated . | P . |
|---|---|---|---|---|
| No. (%) of patients | 36 | 17 (47) | 19 (53) | |
| Age, y | ||||
| Median | 39 | 43 | 36 | |
| Range | (4-76) | (6-76) | (4-68) | |
| Younger than 14 | 4 (11%) | 1 (6%) | 3 (16%) | .6 |
| Sex, no. (%) | ||||
| Male | 24 (67) | 12 (71) | 12 (63) | |
| Female | 12 (33) | 5 (29) | 7 (37) | .73 |
| Diagnosis, no. (%) | ||||
| Burkitt lymphoma | 9 (25) | 5 (29) | 4 (21) | .71 |
| Burkitt lymphoma-leukemia | 27 (75) | 13 (76) | 14 (74) | |
| Stage III/IV, no. (%) | 34 (94) | 17 (100) | 17 (89) | .48 |
| Bulky disease,* no. (%) | 11 (32) | 4 (27) | 7 (37) | .71 |
| Extranodal involvement,* no. (%) | 28 (82) | 12 (80) | 16 (84) | 1 |
| LDH level > 1000 IU,† no. (%) | 21 (66) | 9 (69) | 12 (63) | 1 |
| Complete remission, no. (%) | 19 (53) | 4 (24) | 15 (79) | .002 |
| . | Whole series . | BIM methylated . | BIM unmethylated . | P . |
|---|---|---|---|---|
| No. (%) of patients | 36 | 17 (47) | 19 (53) | |
| Age, y | ||||
| Median | 39 | 43 | 36 | |
| Range | (4-76) | (6-76) | (4-68) | |
| Younger than 14 | 4 (11%) | 1 (6%) | 3 (16%) | .6 |
| Sex, no. (%) | ||||
| Male | 24 (67) | 12 (71) | 12 (63) | |
| Female | 12 (33) | 5 (29) | 7 (37) | .73 |
| Diagnosis, no. (%) | ||||
| Burkitt lymphoma | 9 (25) | 5 (29) | 4 (21) | .71 |
| Burkitt lymphoma-leukemia | 27 (75) | 13 (76) | 14 (74) | |
| Stage III/IV, no. (%) | 34 (94) | 17 (100) | 17 (89) | .48 |
| Bulky disease,* no. (%) | 11 (32) | 4 (27) | 7 (37) | .71 |
| Extranodal involvement,* no. (%) | 28 (82) | 12 (80) | 16 (84) | 1 |
| LDH level > 1000 IU,† no. (%) | 21 (66) | 9 (69) | 12 (63) | 1 |
| Complete remission, no. (%) | 19 (53) | 4 (24) | 15 (79) | .002 |